A Bagust

University of Liverpool — United Kingdom

Economics, Econometrics and Finance · Social Sciences

40h-index5.0kcitations177works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(33), Lung Cancer Treatments and Mutations(22), Lung Cancer Diagnosis and Treatment(13), Coronary Interventions and Diagnostics(12), Diabetes Treatment and Management(12)

Publications174 total

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Health Technology Assessment·2020· 38 citedOpen Access
Workstream 3: graduated compression garments to prevent onset of chronic lymphoedema
2019
Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT
Programme Grants for Applied Research·2019· 1 citedOpen Access
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2019· 1 citedOpen Access
Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer
Medical Decision Making·2018· 4 cited
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics·2018· 14 citedOpen Access
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics·2017· 4 cited
Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen
2017
Policy vs Evidence: A Case Study
2017
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics·2017· 9 cited
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE
Brunel University Research Archive (BURA) (Brunel University London)·2015· 3 citedOpen Access
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
Health Technology Assessment·2015· 41 citedOpen Access
Rates of febrile neutropenia associated with treatment with docetaxel
2015
Table of excluded publications with rationale
2015
Table of included studies and associated publications
2015
Quality assessment of included studies
2015
Details of probabilistic sensitivity analysis: survival model parameters
2015
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation
Health Technology Assessment·2015· 3 citedOpen Access
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
PharmacoEconomics·2015· 8 cited
Definition of the decision problem and patient populations and details of the independent economic model
2015
page 1 of 9Next →

Frequent Co-authors

Angela Boland(28), Y Dündar(24), Rumona Dickson(20), C McLeod(12), J Greenhalgh(12), T Walley(11), Nigel Fleeman(9), C Proudlove(8), Sophie Beale(7), J Oyee(7), Alan Haycox(6), Jo Hockenhull(6), Helen Davis(5), Ruaraidh Hill(4), Rubén Mújica-Mota(4), Juliet Hockenhull(4), C Martin Saborido(4), P. K. Hopkinson(3), Tamara Brown(3), R Dickson(3)